RT for Adenocarcinoma/Adenosquamous Carcinoma (NCT07153952) | Clinical Trial Compass
Active — Not RecruitingPhase 1/2
RT for Adenocarcinoma/Adenosquamous Carcinoma
China60 participantsStarted 2025-01-01
Plain-language summary
This study aims to establish a prospective cohort of locally advanced cervical adenocarcinoma to provide a better way to monitor its efficacy and provide precise treatment. The key problems to be solved are as follows:
1. Establish an observational prospective cohort of locally advanced ADC and randomly divide patients with residual cervical tumors in the primary site after CCRT into the local treatment group (salvage surgery or supplementary radiotherapy) or the systemic treatment group.
2. Collect cervical biopsy tissues before and after CCRT in patients with residual cervical tumors, explore the genomic characteristics, and predict whether they can benefit from targeted/immunotherapy in the future.
Who can participate
Age range18 Years – 80 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Pathological diagnosis of cervical adenocarcinoma;
✓. Age 18-80 years old;
✓. FIGO 2018 stage IB3-IVA;
✓. Karnofsky score≥60 points;
✓. Complete blood count, and comprehensive metabolic panel meet the conditions for CCRT;
✓. No metal implants in the body, and can perform MRI examination;
✓. Willing to participate in this study and provide written informed consent.
Exclusion criteria
✕. Patients who have received pelvic radiotherapy before;
✕. Patients whose target tumors have been treated before (chemotherapy, immunotherapy, surgical treatment, etc.);
✕. Allergy to iodine contrast agent;
✕
What they're measuring
1
Tumor control rate
Timeframe: Tumor control rate among patients with residual cervical tumors in the two groups 3 months after treatment